Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | BAX | Q07812 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27660156 | 0.87 | MMP3 (0.38) | CA1CA2 | |
| SCHEMBL3670294 | 0.83 | NCOA1 (0.34) | — | |
| SCHEMBL19719371 | 0.82 | HPGD (0.44) | TSHR | |
| SCHEMBL21134100 | 0.82 | ALDH1A1 (0.32) | — | |
| SCHEMBL18053430 | 0.82 | CYP3A4 (0.34) | — | |
| SCHEMBL4444463 | 0.82 | CA1 (0.50) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL30810811 | 0.82 | CA1 (0.50) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL4888931 | 0.80 | CA1 (0.48) | TSHRCA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL2154353 | 0.80 | CA1 (0.48) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL28379424 | 0.80 | CA1 (0.48) | TSHRCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409699-B | Novel X-ray luminescent material and preparation method thereof | 南京邮电大学 | 2023-10-20 | — | — | CN | claimed |
| CN-114409699-A | Novel X-ray luminescent material and preparation method thereof | 南京邮电大学 | 2022-04-29 | — | — | CN | claimed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20250026737-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AG (DE) | 2025-01-23 | — | — | US | disclosed |
| US-12195448-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-20240109864-A1 | SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
| US-20240101528-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-28 | — | — | US | disclosed |
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051935-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-15 | — | — | US | disclosed |
| US-20230346777-A1 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | BAYER AG (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-2385942-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254572-A1 | CAPACITANCE-TYPE SENSOR | FUJIKURA LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| CN-102197031-A | Substituted 5-aminopyrazoles and use thereof | BAYER SCHERING PHARMA AG | 2011-09-21 | — | — | CN | disclosed |
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010079120-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020366-A1 | AZABICYCLIC SUBSTITUTED 5-AMINOPYRAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| CN-101119747-A | Tissue factor production inhibitor | SANKYO CO (JP) | 2008-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | LTA4H 2617/4885TSHR 2505/4885CA12 4874/4885 |
| US-20240051935-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | PLOD3, PDK4, PDF | LTA4H 2416/4885TSHR 4041/4885CA12 4823/4885 |
| US-12195448-B2 | Substituted pyrazolo piperidine carboxylic acids | PLOD3, PDK4, PDF | LTA4H 2416/4885TSHR 4041/4885CA12 4823/4885 |
| US-20240109864-A1 | SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS | PLOD3, PDK4, PDF | LTA4H 2383/4885TSHR 4099/4885CA12 4815/4885 |
| US-20230346777-A1 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | PRKG1, PGC, PRKG2 | LTA4H 2852/4885TSHR 696/4885CA12 4795/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | LTA4H 2694/4885TSHR 2440/4885CA12 4765/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | LTA4H 1019/4885TSHR 3887/4885CA12 4470/4885 |
| US-20240101528-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | PLOD3, PDK4, PDF | LTA4H 2416/4885TSHR 4041/4885CA12 4823/4885 |
| US-20250026737-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | PLOD3, PDK4, PDF | LTA4H 2416/4885TSHR 4041/4885CA12 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.